Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

We explored the impact of early molecular response (EMR; BCR-ABL ≤10% on the international scale [BCR-ABL(IS)] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilot...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Hughes, Timothy P., Saglio, Giuseppe, Kantarjian, Hagop M., Guilhot, François, Niederwieser, Dietger, Rosti, Gianantonio, Nakaseko, Chiaki, De Souza, Carmino Antonio, Kalaycio, Matt E., Meier, Stephan, Fan, Xiaolin, Menssen, Hans D., Larson, Richard A., Hochhaus, Andreas
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2014
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624459/
https://ncbi.nlm.nih.gov/pubmed/24335106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-06-510396
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares